SAN FRANCISCO — Medication burden was significantly reduced more in glaucomatous eyes implanted with the Hydrus device vs. two iStent devices at 2 years postoperatively, according to COMPARE trial results presented here.
The multicenter randomized trial compared the Hydrus (Ivantis) with two iStent (Glaukos) devices for stand-alone primary surgical treatment of open-angle glaucoma. Patients under treatment with two or more medications whose IOP remained elevated after preoperative washout, between 23 mm Hg and 39 mm Hg, were randomized 1:1 in the operating room after gonioscopic
Uncategorized